Dewpoint Therapeutics
Kelly is originally from Michigan where she received her B.S. in Biomedical Sciences from Western Michigan University. Over the last twenty years, she has held various roles at Pfizer and Merck in translational and systems biology research, bioinformatics, data sciences and analytics, and IT program management. Most recently she was at Biogen where she implemented the R&D Portfolio and Resource Management system, as well as established and lead the R&D Project Management Office, which provided project management for R&D programs from early research to marketed stages.
Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.